lly

The consensus view prices Lilly's GLP-1 growth correctly but anchors on historical pharma margin profiles. We disagree. The margin expansion is structural: Manufacturing scale economics: Tirzepatide is a peptide produced at increasing scale — unit costs decline 15-25% with each manufacturing doubling SG&A leverage: Commercial infrastructure for diabetes and obesity is already built...

Pillar 1 (40% weight): GLP-1 Revenue Dominance — Mounjaro + Zepbound trajectory to $30-40B by 2027 Pillar 2 (20%): Oral GLP-1 Category Expansion — Orforglipron opens the injectable-averse patient population Pillar 3 (20%): Margin Expansion Through Scale — Path from 30% to 35%+ operating margins Pillar 4 (20%): Pipeline Optionality — Retatrutide, donanemab, oncology, radiopharmaceuticals

Risk: Combined tirzepatide (Mounjaro + Zepbound) quarterly revenue growth decelerates below 15% YoY for two consecutive quarters, signaling demand saturation, competitive loss, or pricing pressure. Trigger: Quarterly earnings reports showing sequential deceleration in GLP-1 new patient starts combined with pricing compression. Action: Exit position...

Risk: A competitor demonstrates equivalent or superior efficacy to tirzepatide with better convenience (monthly dosing, oral, fewer side effects). Amgen's MariTide (monthly) or Novo's CagriSema (25%+ weight loss) are the most likely candidates. Trigger: Phase 3 results from MariTide or CagriSema showing non-inferiority/superiority to tirzepatide with better tolerability or dosing convenience...

Risk: Two or more major pipeline programs (orforglipron, retatrutide, MASH, oncology) fail Phase 3 within 18 months. This would remove the pipeline optionality that justifies the valuation premium over Novo Nordisk. Trigger: Phase 3 failures reported in clinical trial readouts...

Tirzepatide is a once-weekly injectable dual GIP/GLP-1 receptor agonist. Its differentiation from Novo Nordisk's semaglutide (GLP-1 only) is the dual mechanism: GLP-1 agonism: Reduces appetite, slows gastric emptying, improves insulin secretion GIP agonism: Enhances GLP-1 effects on weight loss, additional metabolic benefits, potentially better tolerability In SURPASS-2 (head-to-head vs semaglutide 1mg): tirzepatide achieved 2.01% A1C reduction vs 1.86% and 12.4kg weight loss vs 6.2kg. Crucially, no head-to-head data exists vs semaglutide 2.4mg (Wegovy dose for obesity) — this remains a data gap the market should price.

Trulicity (dulaglutide), once Lilly's largest drug at $7.1B peak revenue (2022), is declining rapidly (-31% YoY) as patients and physicians switch to Mounjaro. This is net positive for Lilly — tirzepatide has higher gross margins and stronger clinical data — but creates a visible revenue drag in the near term. By FY2026, Trulicity revenue will likely be

Novo Nordisk (NVO): Semaglutide franchise (Ozempic + Wegovy) at ~$29B in 2024. First-mover advantage in GLP-1. CagriSema (cagrilintide + semaglutide) showed 25.3% weight loss in Phase 3 — approval expected 2025-2026...

Clinical differentiation: Tirzepatide's dual GIP/GLP-1 mechanism delivers superior weight loss and A1C reduction vs GLP-1-only drugs Manufacturing scale: $20B+ invested in tirzepatide-specific capacity creates a 3-5 year production advantage over new entrants Pipeline depth: Orforglipron (oral) + retatrutide (triple agonist) give Lilly a next-gen product cycle that competitors lack Real-world evidence: Growing body of outcomes data from millions of patients on tirzepatide strengthens physician confidence Moat vulnerability: All advantages are duration-dependent...

The obesity drug market is the fastest-growing category in pharmaceuticals. Key assumptions behind the $100B+ TAM: Prevalence: 42% of US adults are obese (BMI 30+). ~650 million adults globally...

Tirzepatide's clinical program is expanding into indications worth potentially $50B+ in aggregate: MASH/NASH: Phase 2 (SYNERGY-NASH) showed significant improvement in fibrosis and NASH resolution. If approved, competes with Madrigal's Rezdiffra in a $15B+ market. Heart Failure with Obesity: SUMMIT trial showed improvement in heart failure symptoms...

Near-term (2025-2026): Orforglipron: Oral GLP-1, Phase 3 data expected. Potential $10B+ peak sales. Tirzepatide MASH: Phase 3 ongoing...

Donanemab received FDA approval in July 2024 for early symptomatic Alzheimer's disease. It targets amyloid plaques and demonstrated 35% slowing of clinical decline in the TRAILBLAZER-ALZ 2 trial. The issue: Commercial uptake has been slower than expected due to ARIA monitoring requirements (brain swelling/bleeds requiring regular MRIs), limited diagnostic infrastructure, and competition from Eisai/Biogen's Leqembi...

Lilly's manufacturing expansion is the most critical execution variable for the investment thesis: Lebanon, Indiana ($3.7B): Largest investment. New API and drug product facility. Expected operational 2025-2026...

While tirzepatide has been on the FDA drug shortage list, compounding pharmacies have legally produced unapproved versions. Key considerations: Compounded tirzepatide is available at 50-80% discount to branded prices FDA enforcement has been inconsistent — some pharmacies shut down, others continue Once Lilly resolves the shortage, FDA will likely crack down on compounders Estimated 5-10% of current demand is served by compounders Net impact: Negative near-term (revenue leakage) but likely resolved by 2025-2026 as supply normalizes.

What: Orforglipron is a non-peptide oral GLP-1 receptor agonist — a daily pill that could replace weekly injections. Phase 2 showed up to 14.7% body weight loss. Why it matters: An effective oral GLP-1 could expand the addressable patient population 3-5x by eliminating the injection barrier...

What: Retatrutide is a GIP/GLP-1/glucagon triple receptor agonist that showed up to 24.2% body weight loss in Phase 2 — potentially the most efficacious obesity drug ever tested. Why it matters: If Phase 3 confirms Phase 2, retatrutide would be the best-in-class injectable and extend Lilly's GLP-1 franchise well into the 2030s, even after tirzepatide patents expire. The glucagon component adds metabolic benefits beyond weight loss (MASH, fatty liver disease)...

Consensus underestimates: Operating margin expansion. Street models ~30-32% operating margins for FY2025-2027. We model 35%+ by FY2027 as manufacturing scale economics and SG&A leverage compound...

Mounjaro quarterly revenue: Sequential growth rate indicates demand trajectory. Target: >$3.5B/quarter in 2025 Zepbound quarterly revenue: New patient starts vs refills. Supply constraint relief = revenue acceleration...

LLY positioning is maximally bullish: 0 Sell ratings, 0.8% short interest, 82% institutional ownership. Any negative catalyst triggers amplified selling. Size accordingly.

CEO David Ricks holds significant equity (~$50M+). Insider selling has been routine (diversification) rather than signal-driven. No unusual insider activity detected.

Options flow shows consistent call buying in Jan 2026 expiry, particularly $1,000-$1,200 strikes. Institutional accumulation visible in 13F filings — hedge fund ownership increasing. Dark pool activity normal.

The decision to develop tirzepatide (a dual GIP/GLP-1 agonist) was a bold scientific bet. At the time, the GLP-1 market was dominated by Novo Nordisk's semaglutide, and the contribution of GIP agonism to metabolic outcomes was debated. Lilly's scientists hypothesized that dual agonism would produce superior results — and they were right...

In March 2023, Lilly voluntarily cut insulin list prices by 70% and capped out-of-pocket costs at $35/month. This was a $1.5-2B annual revenue sacrifice that was strategically brilliant: Pre-empted political attacks on drug pricing Generated massive positive press coverage globally Reduced the political target on GLP-1 pricing (which is far more profitable) The revenue loss was easily absorbed by tirzepatide ramp This decision signals management's strategic sophistication — willing to sacrifice legacy revenue to protect the GLP-1 franchise from political backlash.

David Ricks became CEO in January 2017 at age 49 — young for a pharma CEO...

At 70x forward P/E, LLY behaves like a long-duration asset. The present value of distant future earnings (FY2028-2030 GLP-1 peak revenue) is highly sensitive to discount rate changes: Each 50bps increase in 10Y yield → ~5-7% downside for LLY A sharp rise to 5.5% (from 4.35% current) would compress growth multiples sector-wide, hitting LLY disproportionately Mitigant: LLY's growth rate (32% revenue) compresses the effective duration. If growth continues, P/E compresses naturally regardless of rate environment.

The Inflation Reduction Act's Medicare drug price negotiation applies to drugs marketed for 9+ years (small molecule) or 13+ years (biologics). Impact on Lilly: Jardiance: Selected for first round of negotiation. Negotiated price effective 2026...

10,000-iteration Monte Carlo simulation with randomized assumptions: Revenue CAGR: 15-30% (5Y), normal distribution centered at 22% Terminal margin: 28-40%, centered at 35% WACC: 5.5-8.0%, centered at 6.5% Pipeline success: Bernoulli trials for orforglipron (65% probability) and retatrutide (55%) Results: Mean $1,020, median $990. 58% probability above current price ($870). Fat left tail driven by pipeline failure scenarios...

Structure: Buy Jan 2026 $900 call, sell Jan 2026 $1,100 call. Cost: ~$60-70/share. Rationale: Captures upside to $1,100 (+26%) while capping cost at $60-70 per share (~7% of stock price)...

For existing LLY holders concerned about pipeline binary risk: Structure: Buy Jan 2026 $750 put (~$30/share) for catastrophic downside protection Rationale: Protects against 14%+ drawdown from pipeline failure or competitive setback Cost: ~3.5% of position value annualized — the insurance premium for owning a 70x P/E stock with binary catalysts

CEO David Ricks received ~$26M in FY2023 total compensation, with 74% tied to performance metrics: Revenue growth targets: Tied to GLP-1 franchise ramp 3-year relative TSR: vs. pharma peer group Pipeline milestones: Phase 3 completions and regulatory approvals Compensation is well-structured and aligned with shareholder interests. The emphasis on revenue growth (not just earnings) correctly incentivizes the current strategy of reinvesting aggressively in GLP-1 manufacturing and pipeline.

Lilly has strong ESG positioning, bolstered by the 2023 insulin price cut decision: Access & affordability: 70% insulin price cut, $35/month cap. GLP-1 patient assistance programs. Environmental: Carbon neutrality targets, green manufacturing investments...

Conviction: 75/100. Not a maximum-conviction position due to valuation premium and crowded positioning. Recommended sizing: 3-5% of portfolio...